REFERENCES
- Ian RW, George S, Amar PD, Maria G, Artonio P, Renzo GM, Rita G, Elas S, Alan RC. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent thalassemia. Blood 2002; 100(5)1566–1569, [CSA]
- Risdon RA, Barry M, Flynn DM. Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassemia. J Pathol 1975; 116(2)83–95, [INFOTRIEVE], [CROSSREF], [CSA]
- Forget BG. Thalassemia syndrome. Hematology Basic Principles and Practice3rd, R Hoffman, EJ Benz, SJ Shathl, B Furie, HJ Cohen, LE Silberstein, P McGlare. Churchill Livingstone, Philadelphia 2000; 485–510
- Ardalan FA, Osquei MRF, Toosi MN, Guiti I. Synergic effect of chronic hepatitis C infection and β thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective cross-sectional study. BMC Gastroenterol 2004; 4: 17–20, [INFOTRIEVE], [CROSSREF], [CSA]
- Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, Bissoli F, Ceriani R, Ballare M, Massari M, Trischitta C, Fiore P, Orlandi A, Morini L, Mattioli M, Oldani S, Cesana B, Fiorelli G. Iron reduction and sustained response to interferon-α therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol 2002; 97(5)1204–1210, [INFOTRIEVE], [CSA]
- Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 2002; 36(5)678–691, [CROSSREF], [CSA]
- Peng CT, Chow KC, Chen JH, Chiang YP, Tsai CH. Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan. Eur J Hematol 2003; 70(6)392–397, [CROSSREF], [CSA]
- Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103(2)361–364, [INFOTRIEVE], [CROSSREF], [CSA]
- Porter JB, Hoyes KP, Abeysinghe RD, Brooks PN, Huehns ER, Hider RC. Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice. Blood 1991; 78(10)2727–2734, [INFOTRIEVE], [CSA]
- Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102(1)17–23, [INFOTRIEVE], [CROSSREF], [CSA]
- Scarle J, Kerr J, Halliday J, Powell L. Iron storage disease. Pathology of the Liver, R MacSween, P Anthony, P Scheuer, A Burt, B Portmann. Churchill Livingstone, Edinburgh 1994; 219–241
- Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program) 2003; 46–61, [CSA]
- Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappelini MD, Verlato G. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998; 850: 227–231, [INFOTRIEVE], [CROSSREF], [CSA]
- Nancy FO, Gray MB, Doreen M, Matitiahu B, Laurence MB, Ross GM, Robert AM, Peter PL, Douglas MT, Gideon K. Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332(14)918–922, [CROSSREF], [CSA]
- Hoffbrand AV, Al Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91(1)295–300, [INFOTRIEVE], [CSA]
- Maggio A, D'Amico G, Morabito A, Ciacio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, Giuseppe D, Ascola D, Rizzo A, Midiri M. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28(2)196–208, [INFOTRIEVE], [CROSSREF], [CSA]